Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)
China · Delayed Price · Currency is CNY 20.28
-0.53 (-2.55%)
Aug 31, 2026, 3:04 PM CST
SHE:002773 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 19,173 | 27,612 | 18,028 | 16,955 | 14,426 | 18,711 | |
Market Cap Growth | -48.91% | 53.16% | 6.33% | 17.53% | -22.90% | -57.83% |
Enterprise Value | 12,800 | 21,206 | 12,488 | 12,473 | 11,281 | 15,524 |
Last Close Price | 20.81 | 28.95 | 18.56 | 17.17 | 14.51 | 18.69 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 19.27 | 23.74 | 15.13 | 16.23 | 16.09 | 44.44 |
Forward PE | - | 20.81 | 13.38 | 15.30 | 12.75 | 17.93 |
PS Ratio | 4.45 | 6.02 | 4.05 | 4.28 | 4.26 | 5.19 |
PB Ratio | 2.09 | 2.98 | 2.09 | 2.17 | 2.09 | 3.07 |
P/TBV Ratio | 2.16 | 3.09 | 2.15 | 2.27 | 2.20 | 3.22 |
P/FCF Ratio | 24.12 | 22.25 | 14.39 | 15.71 | 25.31 | - |
P/OCF Ratio | 17.00 | 18.36 | 12.77 | 13.92 | 15.59 | 37.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.97 | 4.63 | 2.81 | 3.15 | 3.33 | 4.31 |
EV/EBITDA Ratio | 9.81 | 14.20 | 8.55 | 9.44 | 11.05 | 28.00 |
EV/EBIT Ratio | 12.11 | 16.86 | 10.13 | 11.33 | 13.05 | 38.14 |
EV/FCF Ratio | 16.10 | 17.09 | 9.97 | 11.55 | 19.79 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0 | 0 | 0.00 | 0 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Debt / FCF Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | - |
Net Debt / Equity Ratio | -0.69 | -0.69 | -0.66 | -0.60 | -0.53 | -0.51 |
Net Debt / EBITDA Ratio | -4.87 | -4.31 | -3.89 | -3.56 | -3.61 | -5.65 |
Net Debt / FCF Ratio | -7.97 | -5.18 | -4.54 | -4.35 | -6.46 | 41.59 |
Asset Turnover | 0.44 | 0.48 | 0.50 | 0.49 | 0.46 | 0.52 |
Inventory Turnover | 1.21 | 1.18 | 1.19 | 1.20 | 1.25 | 1.33 |
Quick Ratio | 9.36 | 11.07 | 8.99 | 7.46 | 5.59 | 5.08 |
Current Ratio | 10.03 | 11.77 | 9.60 | 8.11 | 6.10 | 5.54 |
Return on Equity (ROE) | 10.85% | 12.78% | 14.30% | 14.01% | 13.31% | 7.10% |
Return on Assets (ROA) | 6.79% | 8.16% | 8.62% | 8.47% | 7.36% | 3.65% |
Return on Invested Capital (ROIC) | 31.14% | 36.59% | 35.31% | 29.02% | 23.44% | 15.07% |
Return on Capital Employed (ROCE) | 11.50% | 13.50% | 14.20% | 14.00% | 12.30% | 6.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.21% | 4.21% | 6.61% | 6.16% | 6.21% | 2.25% |
FCF Yield | 4.15% | 4.50% | 6.95% | 6.37% | 3.95% | -0.40% |
Dividend Yield | 3.17% | 2.42% | 3.23% | 2.21% | 1.03% | 0.53% |
Payout Ratio | 50.05% | 47.52% | 29.33% | 13.20% | 10.25% | 21.84% |
Buyback Yield / Dilution | -0.80% | -0.73% | 0.01% | -0.16% | 0.05% | -5.16% |
Total Shareholder Return | 2.37% | 1.69% | 3.25% | 2.05% | 1.08% | -4.62% |